



Page 1 of 3

IN THE UNITED STATES PATI NT & TRADEMARK OFFICE

In re application

Per-Ake Nygren, Mathias Uhlen and Olof Nord

Serial No.

10/030,652

Filed

November 9, 2001

For

SELF-ASSEMBLING BIOMOLECULAR

STRUCTURES

Examiner

Attorney Docket

Group Art Unit

Confirmation No.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents,

Washington, D.C. 20231 on Z3 AUG ZOOZ

By Todd E

Todd E. Garabedian, Ph.D. Registration No. 39,197 Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents United States Patent and Trademark Office Washington, DC 20231

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- [X] 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- [] 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - [] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
 - [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
 - [] Please charge Deposit Account No. <u>23-1665</u> in the amount of \$240.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
 - [] A check in the amount of \$240.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).
- [] 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
 - [] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
 - [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than

three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

- [] Please charge Deposit Account No. 23-1665 in the amount of \$130.00 in payment of the fee under 37 C.F.R. \$1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. \$1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

PER-AKE NYGREN, MATHIAS UHLEN AND OLOF NORD

By Todd E. Garabedian, Ph.D.

Registration No. 39,197 Attorney for Applicants

WIGGIN & DANA LLP

One Century Tower

New Haven, CT 06508-1832

Telephone: (203) 498-4400 Telecopier: (203) 782-2889

Date: 23 AVG ZOOZ

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				3 TY. DOCKET NO. 102359-100		SERIAL NO. 10/030,652		
			APPLICANTS: P	APPLICANTS: PER-AKE NYGREN, MATHIAS UHLEN AND OLOF NORD				
			FILING DATE: N	FILING DATE: November 9, 2001		GROUP:		
			U.S. PATENT DOCU	MENTS				
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING D.		
		ļ						
								
· · · · · · · · · · · · · · · · · · ·		<u> </u>						
						-		
			FOREIGN PATENT DO	CUMENTS				
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA Yes No		
		<u> </u>						
	OTHER DOG	In Correction	LUDDIG AVENOR					
			LUDING AUTHOR, TIT					
~	NORD, K ET AL: NATURE BIOTECHNOLOGY, vol. 15, no. 8, August 1997 (1997-08), pages 772-777.							
N	PETKA, W A ET AL: SCIENCE, vol. 281, 17 June 1998 (1998-06-17), pages 38 392.							
N	VOSS, S and SKERRA, A: PROTEIN ENGINEERING, vol. 10, no. 8, 1997, pa 975-982.							
~	NORD, K ET AL: JOURNAL OF BIOTECHNOLOGY, vol. 80, 2000, pages 4 54.							
N	GUNNERIUSSON, E ET AL: PROTEIN ENGINEERING, vol. 12, no. 10, October 1999 (1999-10), pages 873-878.							
N	GROB, P ET 10), pages 15	AL: IMM	IUNOTECHNO	LOGY, vol. 4,	no. 2, Octobe	r 1998 (1		



DT20 Rec'd PCT/PTO : 9 MAY 2003

Page 1 of 3

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application

Per-Åke Nygren, Mathias Uhlén and Olof Nord

Serial No.

10/030,652

Filed

November 9, 2001

For

SELF-ASSEMBLING BIOMOLECULAR

STRUCTURES

Examiner

Attorney Docket

102359-100

Group Art Unit

Confirmation No.

4666

Rν

Todd E. Garabedian, Ph.D. Registration No. 39,197 Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. A copy of each reference (if not previously submitted) is enclosed. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

[X] 1. This Information Disclosure Statement is being filed within three months of the U. S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- [] 2. This Information Disclosure Statement is being filed more than three months after the U. S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - [] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
 - [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
 - Please charge Deposit Account No. <u>23-1665</u> in the amount of \$240.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
 - [] A check in the amount of \$240.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).
- [] 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
 - [] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

- [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- [] Please charge Deposit Account No. <u>23-1665</u> in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. \$1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. \$1.56(b).

Respectfully submitted,

PER-ÅKE NYGREN, ET AL.

Date: 6 MAY 2003

Rv.

Todd E. Garabedian, Ph.D. Registration No. 39,197 Attorney for Applicants

WIGGIN & DANA LLP One Century Tower New Haven, CT 06508-1832

Telephone: (203) 498-4400 Telecopier: (203) 782-2889

STATEMEN	APPLICANT		ATTY. DOCKET NO	. 102359-100	SERIAL NO. 10	0/030,652	
UNY 1 9 201	- - -1	STATEMENT APPLICANT			ATTY. DOCKET NO. 102359-100 SERIAL NO. 10/030,652		
MAY 1 9 2003			APPLICANT: PER-ÅKE NYGREN, MATHIAS UHLÉN and OLOF NORD				
			FILING DATE: Nov	ember 9, 2001	GROUP:		
A TRADEUI	, riv	Ţ	U.S. PATENT DOCUMEN	TS			
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPR.	
N	5,9670,483	09/23/97	Zhang, Shuguang, et al.		-7/08		
		FOI	REIGN PATENT DOCUM	ENTS	· <u>·</u>	- 	
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Yes No	
~	WO 95/19374	07/20/95	· wo	-C07K	14/705-	Yes	
	OTHER DOC	UMENTS (INCLUI	DING AUTHOR, TITLE, D	ATE, PERTINENT	PAGES, ETC.)		
~	HOOGENBOOM, H R ET AL: IMMUNOTECHNOLOGY, Vol. 4, Pages 1-20 (1998).						
~	STAHL, S and NYGREN, P-A: PATOLOGIE BIOLOGIE, Vol. 45, Pages 66-76 (1997).						
~	JANSSON, B ET AL: FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, Vol. 20, Pages 69-78 (1998).						
N	NYGREN, P-A and UHLEN, M: CURRENT OPINION IN STRUCTURAL BIOLOGY, Vol. 7, Pages 463-469 (1997).						
\sim	CORTESE, R ET AL: CURRENT OPINION IN BIOTECHNOLOGY, Vol. 6, Pages 73-80 (1995).						
~	CLACKSON, T and WELLS, J A: TRENDS IN BIOTECHNOLOGY, Vol. 12, Pages 173-184 (1994).						
~	SMITH, G P and PETRENKO, V A: AMERICAN CHEMICAL SOCIETY, Vol. 97, Pages 391-410 (1997).						
~	HANES, J and PLUCKTHUN, A: In Vitro selection and evolution of functional proteins by using ribosome display, PROCEEDINGS, NATIONAL ACADEMY OF SCIENCES OF THE USA, Vol. 94, Pages 4937-4942 (May, 1997).						
~	SCHATZ, P J: BIOTECHNOLOGY, Vol. 11, Pages 1138-1143 (October, 1993).						
N	ROBERTS, R W and SZOSTAK, J W: RNA-peptide fusions for the <i>in vitro</i> selection of peptides and proteins, PROCEEDINGS, THE NATIONAL ACADEMY OF SCIENCES OF THE USA, Vol. 94, Pages 12297-12302 (November, 1997).						
~	McBRIDE, J D ET AL: JOURNAL OF MOLECULAR BIOLOGY, Vol. 259, Pages 819-827 (1996).						
~	NORD, K ET AL: PROTEIN ENGINEERING, Vol. 8, Issue 6, Pages 601-608 (1995).						
\sim	LU, Z ET AL: BIOTECHNOLOGY, Vol. 13, Pages 366-372 (April, 1995).						
EXAMINER:		VARRO		DATE CONSIDER		<u>'</u> 0<	

Page 2 of 2

INFORMATION PISCLOSURE STATEMENT BY APPLICANT MAY 1 9 2003			ATTY. DOCKET NO. 102359-100 SERIAL NO. 10/030,652			/030,652	
			APPLICANT: PER-ÅKE NYGREN, MATHIAS UHLÉN and OLOF NORD				
			FILING DATE: No	vember 9, 2001	GROUP:		
100	4161:		U.S. PATENT DOCUME	NTS			
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPR.	
	<u> </u>	<u> </u>					
		FO	REIGN PATENT DOCUM	MENTS			
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Yes No	
	1		DING AUTHOR, TITLE,				
~	BODER, E T and WITTRUP, K D: NATURE BIOTECHNOLOGY, Vol. 15, Pages 553-557 (June, 1997).						
~	ERNST, W ET AL: NUCLEIC ACIDS RESEARCH, Vol. 26, No. 7, Pages 1718-1728 (1998).						
~	GRABHERR, R ET AL: BIOTECHNIQUES, Vol. 22, Pages 730-735 (April, 1997).						
N	RUTHER, U: NUCLEIC ACIDS RESEARCH, Vol. 10, No. 19, Pages 5765-5772 (1982).						
N	NYGREN, P-A ET AL: JOURNAL OF MOLECULAR RECOGNITION, Vol. 1, No. 2, Pages 69-74 (1988).						
~	CAROTHERS, A M ET AL: BIOTECHNIQUES, Vol. 7, No.5, Pages 494-499 (1989).						
						7,	
					· <u> </u>		
				· · · · · · · · · · · · · · · · · · ·			
EXAMINER:	rare N	AVARRO		DATE CONSIDERE	D: 1/26/0		
*EXAMINER: Initial	if citation considered, who opy of this form with nex	hether or not citation	n is in conformance with No applicant.		rough citation if not in	conformance and not	